CHI-MAW LINLIH-CHYUN CHANGShau, Wen-YiWen-YiShauCHI-LING CHENYao, Chi-YuanChi-YuanYaoFENG-MING TIEN2023-05-302023-05-302023-05-161471-2407https://scholars.lib.ntu.edu.tw/handle/123456789/631518Upfront high-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains a profitable strategy for newly diagnosed multiple myeloma (MM) patients in the context of novel agents. However, current knowledge demonstrates a discrepancy between progression-free survival (PFS) and overall survival (OS) benefit with HDT/ASCT.enAutologous stem-cell transplantation; Meta-analysis; Multiple myeloma; Survival; Systematic review[SDGs]SDG3Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysisjournal article10.1186/s12885-023-10907-1371939782-s2.0-85159428922https://api.elsevier.com/content/abstract/scopus_id/85159428922